In the future, IDH inhibitors might provide an additional therapeutic option for the treatment of IBD-associated CRC, which exhibit a IDH 1 mutation rate of 7% (IBD-associated CRC) and 11% (colitis-associated CRC), respectively [134,135]. This evidence concerns the gene IDH2 and colorectal carcinoma.